



Myrexis to Present at 2011 Rodman and Renshaw Healthcare Conference

SALT LAKE CITY, Sept. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced that Robert Lollini, President and Chief Executive Officer, will be presenting at the 2011 Rodman and Renshaw Annual Healthcare Conference being held September 11-13, at the Waldorf=Astoria Hotel in New York City. Mr. Lollini will be available to participate in one-on-one meetings with investors registered to attend the conference.

Event: **2011 Rodman and Renshaw Annual Healthcare Conference**

Date: Monday, September 12, 2011

Time: 1:35 pm (EDT) (Room: Metropolitan West)

Location: Waldorf Astoria, 301 Park Ave, New York, 10022

The presentation will be webcast live and can be accessed by visiting the investor relations section of Myrexis' website at www.myrexis.com, or via the following link: <http://www.wsw.com/webcast/rrshq20/myrx>. The webcast will be archived for 90 days.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Additional information about Myrexis is available through its corporate website, www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=9929>

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled participation in the 2011 Rodman and Renshaw Annual Healthcare Conference, taking place on September 12, 2011, and statements relating to the attributes and potential efficacy, and the expected timing of development and reporting of data of Myrexis' product candidates. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Wayne Laslie

Chief Operating Officer

801-214-7822

investor.relations@myrexis.com

The Ruth Group

Stephanie Carrington/Joshua Drumm, PhD (investors)

(646) 536-7017/(646) 536-7006

scarrington@theruthgroup.com/

jdrumm@theruthgroup.com

Victoria Aguiar (media)

(646) 536-7013

vaguiar@theruthgroup.com